SLC5A2 and cardiovascular disorder: To illustrate these points, we will focus on a single drug, empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been highly marketed in lay and medical media, has been incorporated into professional society treatment guidelines, and is discussed in more detail in this issue (see “The Evolution of Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure” by Talha, Butler et al.).